
    
      Phase 1, single-center, open-label, randomized, crossover clinical trial to evaluate insulin
      exposure using the 3 U/mg and 4 U/mg Technosphere Insulin Inhalation Powder formulations
      administered using the Gen2 inhaler in 31 healthy volunteers. Drop outs will be replaced.
      Each subject will undergo a screening visit and either 4 or 5 days of in clinic stay and
      dosing, depending on randomization schedule.
    
  